Financial Data and Key Metrics Changes - In Q4 2025, the company reported a revenue of $61.6 million, a 17% increase compared to Q4 2024 [22] - Full year 2025 revenue growth was 15%, with adjusted EBITDA increasing by nearly 75% [8] - The company generated $10 million in free cash flow in Q4 2025, marking its first positive free cash flow quarter in history [7][28] - The gross profit margin improved to 73% in Q4 2025, up from 68% in Q4 2024 [25] Business Line Data and Key Metrics Changes - The Trauma and Deformity (T&D) business grew by 17% in Q4 2025, driven by strong sales of flagship products [11] - Scoliosis revenue increased by 13% in Q4 2025, supported by international implant growth [24] - The Specialty Bracing (OPSB) business continued to be a strategic growth catalyst, with strong same-store sales growth and successful new product launches [14] Market Data and Key Metrics Changes - U.S. revenue was $48.6 million in Q4 2025, a 13% increase, representing 79% of total revenue [23] - International revenue reached $13.0 million, a 33% increase, accounting for 21% of total revenue [23] - The company experienced strong demand in direct markets in the EU and Australia, with a rebound in Latin America [19] Company Strategy and Development Direction - The company aims to help 1 million children annually and is focused on expanding its product portfolio and market presence [9] - A multi-year product innovation cycle is underway, with significant product launches planned [10] - The company is exploring opportunities in pediatric subspecialties beyond orthopedics, including cardiovascular technologies [44][73] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining revenue growth and achieving cash flow breakeven in 2026 [8][28] - The company anticipates continued share gains and improved EBITDA margins driven by new product launches [10][11] - Management highlighted the importance of the EU MDR approvals for expanding product offerings in Europe [20][88] Other Important Information - The company recorded a GAAP net loss per share of $0.43 in Q4 2025, an improvement from $0.69 in the prior year [26] - Non-GAAP net loss per share was $0.30, compared to $0.29 in the same period last year [27] - The company is committed to maintaining a strong R&D pipeline, with several innovative products expected to launch in the coming years [80] Q&A Session Summary Question: Insights on Scoliosis performance and competitive pressure - Management noted strong performance in the Scoliosis segment, driven by the VerteGlide system and new product launches, with expectations for continued growth [33][34] Question: Outlook on margin progression - Management indicated that gross margins are expected to remain around 73% in 2026, with adjusted EBITDA projected to increase significantly [36] Question: Exploration of options to increase shareholder value - Management emphasized the potential for expanding the commercial footprint into other pediatric subspecialties, leveraging existing infrastructure [42][44] Question: Updates on 7D placements and strategy - Management reported normal growth in 7D placements, with optimism for 2026 based on strong performance in existing accounts [55] Question: Impact of new product launches on guidance - Management stated that while there is significant interest in new products, minimal revenue from these launches is included in the 2026 guidance [57] Question: Pricing and margin impact from new products - Management confirmed that new technologies are commanding higher premiums, which will positively impact profitability over time [87] Question: EU MDR strategy and market penetration - Management highlighted the importance of having a full range of product sizes approved in Europe, which will facilitate surgeon conversions and drive growth [88] Question: Cardiovascular business margin profile - Management indicated that the gross margin profile for the cardiovascular business is expected to be higher than the current implant business, which is encouraging for future profitability [90]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported a revenue of $61.6 million, a 17% increase compared to Q4 2024 [22] - Full year 2025 revenue growth was 15%, with a nearly 75% increase in Adjusted EBITDA [8] - The company generated $10 million in free cash flow in Q4 2025, marking its first positive free cash flow quarter in history [7][28] - The gross profit margin improved to 73% in Q4 2025, up from 68% in Q4 2024 [25] - GAAP net loss per share was $0.43, an improvement from $0.69 in the prior year [26] Business Line Data and Key Metrics Changes - The Trauma and Deformity (T&D) business grew by 17% in Q4 2025, driven by flagship products [11] - Scoliosis revenue increased by 13% in Q4 2025, supported by international growth and OPSB [24] - The OPSB business continued to be a strategic growth catalyst, with strong same-store sales growth and successful new product launches [14] Market Data and Key Metrics Changes - U.S. revenue was $48.6 million, a 13% increase from Q4 2024, representing 79% of total revenue [23] - International revenue reached $13.0 million, a 33% increase compared to Q4 2024, representing 21% of total revenue [23] Company Strategy and Development Direction - The company aims to help 1 million children annually and is focused on expanding its product portfolio and market presence [9] - A multi-year super cycle of product innovation is underway, with significant product launches planned [10] - The company is exploring opportunities in pediatric subspecialties beyond orthopedics, including cardiovascular technologies [44][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining revenue growth and achieving cash flow breakeven in 2026 [8][28] - The company anticipates continued strong performance in the scoliosis segment, driven by new product launches and market expansion [34] - Management highlighted the importance of the EU MDR approvals for enhancing international market penetration [20][89] Other Important Information - The company is committed to maintaining a strong R&D pipeline, with several innovative products expected to launch in the coming years [80] - The acquisition of a Brazilian distributor is expected to improve cash collection and market penetration in Latin America [20] Q&A Session Summary Question: Insights on Scoliosis performance and competitive pressure - Management noted strong growth in the scoliosis segment, driven by new product launches and increased surgeon adoption [33] Question: Outlook on margin progression - Management expects gross margins to remain around 73% in 2026, with Adjusted EBITDA projected to increase significantly [36] Question: Exploration of options to increase shareholder value - Management indicated interest in expanding the commercial footprint in pediatric subspecialties and leveraging existing capabilities [42][44] Question: Updates on new product launches and guidance - Management stated that while new product launches are not heavily factored into guidance, there is significant interest and potential for future revenue [57] Question: Pricing and margin impact from new products - New technologies are expected to command higher premiums, positively impacting profitability over time [87] Question: Impact of EU MDR approvals on international growth - The approval allows for a full range of product sizes, facilitating surgeon conversion and enhancing growth in the European market [88]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported a revenue of $61.6 million, reflecting a 17% increase compared to Q4 2024 [20] - Full year 2025 revenue growth was 15%, with adjusted EBITDA increasing nearly 75% [6] - The company generated $10 million in free cash flow in Q4 2025, marking its first positive free cash flow quarter in history [6][25] - The gross profit margin improved to 73% in Q4 2025, up from 68% in Q4 2024 [22] Business Line Data and Key Metrics Changes - The Trauma and Deformity (T&D) business grew by 17% in Q4 2025, with global revenue reaching $42.6 million [21] - Scoliosis revenue increased by 13% to $17.6 million in Q4 2025, driven by international implant growth [21] - The Specialty Bracing (OPSB) business continued to support revenue growth and profitability, with strong same-store sales growth [12] Market Data and Key Metrics Changes - U.S. revenue was $48.6 million in Q4 2025, a 13% increase, representing 79% of total revenue [20] - International revenue reached $13.0 million, a 33% increase, accounting for 21% of total revenue [20] Company Strategy and Development Direction - The company aims to help 1 million children annually and is focused on expanding its product portfolio and market presence [7] - A multi-year product innovation cycle is underway, with significant product launches planned, including the 3P Hip and VerteGlide systems [8] - The company is exploring opportunities in other pediatric subspecialties to leverage its commercial footprint [41][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining revenue growth and achieving cash flow breakeven in 2026 [6] - The company anticipates continued share gains and improved EBITDA margins due to new product launches and operational efficiencies [8][33] - Management highlighted the positive surgeon feedback on new products, indicating strong market acceptance [16][75] Other Important Information - The company made structural improvements in Brazil through the acquisition of a distributor, which is expected to enhance cash collection and market penetration [18] - The company is also advancing into the digital health space with the launch of the Playbook platform, aimed at improving surgical efficiency [60] Q&A Session Summary Question: Insights on Scoliosis performance and competitive pressure - Management noted strong growth in the Scoliosis segment, driven by new product launches and increased surgeon adoption [29][30] Question: Outlook on margin progression - Management expects gross margins to remain around 73% in 2026, with adjusted EBITDA projected to increase to $25 million [33] Question: Exploration of options to increase shareholder value - Management indicated interest in expanding the commercial footprint into other pediatric subspecialties, leveraging existing infrastructure [40][41] Question: Updates on 7D placements and strategy - Management reported normal growth in 7D placements, with optimism for 2026 based on strong performance in existing accounts [51] Question: Pricing and margin impact from new product launches - New technologies are expected to command higher premiums, positively impacting profitability over the coming years [82] Question: EU MDR strategy and its impact on OUS market - The approval of a full product range in Europe is anticipated to enhance growth and conversion rates among surgeons [83] Question: Cardiovascular business margin profile - The cardiovascular segment is expected to have a higher gross margin profile compared to the current implant business [85]

Summary of OrthoPediatrics Conference Call Company Overview - **Company Name**: OrthoPediatrics (NasdaqGM: KIDS) - **Industry**: Pediatric Orthopedics - **Focus**: Solely dedicated to pediatric orthopedic solutions, with no involvement in adult orthopedic products [2][3] Key Points and Arguments - **Market Impact**: OrthoPediatrics has helped a cumulative total of 1.3 million children, with a goal to assist over 150,000 children in 2025 and an objective to reach 1 million annually in the future [2][3] - **Unique Product Development**: The company has developed products specifically designed for pediatric patients, addressing unique clinical conditions such as curved bones, which differ significantly from adults [2][3] - **Market Size**: The global pediatric orthopedic market is estimated to be around $6 billion, with significant segments including trauma and deformity, scoliosis, specialty bracing, and enabling technology [5] - **Sales Strategy**: OrthoPediatrics focuses exclusively on children's hospitals in the U.S., which number approximately 300-400, avoiding adult hospitals entirely [5][6] - **Sales Force**: The company employs over 230 sales agents in the U.S. and sells products in over 75 countries, supported by an additional 200 individuals servicing those hospitals [4][5] Product Portfolio and Innovations - **Product Range**: The company has expanded its product offerings from 17 at the time of its IPO in 2017 to over 80 systems currently available [14][22] - **Recent Acquisitions**: Notable acquisitions include Firefly (navigation system for scoliosis), Appifix (internal brace for scoliosis), and Boston O&P (specialty braces and clinics) [9][10][18] - **New Technologies**: Introduction of innovative products such as the VertiGlide system for severe early-onset scoliosis and the DF2 Brace for hip dysplasia, which replaces traditional spica casts [16][17] Financial Performance - **Revenue Growth**: The company has consistently achieved over 20% annual growth, with a projected growth rate of 14% for 2025 [19][21] - **EBITDA Guidance**: For 2025, the company expects adjusted EBITDA between $15 million and $17 million, a significant increase from $8.5 million the previous year [21][22] - **Cash Flow Management**: OrthoPediatrics aims to achieve positive free cash flow in Q4 2025 and break-even in 2026, having reduced cash usage significantly from $40 million two years ago to an expected $20 million this year [23][24] Strategic Focus - **Clinical Education Commitment**: The company emphasizes the importance of clinical education, hosting over 300 training sessions annually for surgeons and clinicians [4][13] - **Market Expansion**: Plans to continue expanding both product offerings and clinic presence, with a focus on specialty bracing, which is projected to grow over 20% annually for the next three to five years [19][18] Conclusion - OrthoPediatrics is positioned as a leader in the pediatric orthopedic market, with a strong commitment to innovation, clinical education, and strategic growth through acquisitions and product development [22][24]